Home/Filings/4/0000907654-26-000004
4//SEC Filing

Goncalves Joana 4

Accession 0000907654-26-000004

CIK 0000907654other

Filed

Jan 15, 7:00 PM ET

Accepted

Jan 16, 5:26 PM ET

Size

14.3 KB

Accession

0000907654-26-000004

Insider Transaction Report

Form 4
Period: 2026-01-15
Goncalves Joana
Chief Medical Officer
Transactions
  • Exercise/Conversion

    Common Stock

    2026-01-15$6.84/sh+3,500$23,9405,018 total
  • Exercise/Conversion

    Common Stock

    2026-01-15$7.80/sh+3,500$27,3008,518 total
  • Sale

    Common Stock

    [F1][F2]
    2026-01-15$31.56/sh4,381$138,2764,137 total
  • Sale

    Common Stock

    [F1][F3]
    2026-01-15$32.24/sh2,619$84,4291,518 total
  • Exercise/Conversion

    Employee Stock Option (right to buy)

    [F4]
    2026-01-153,500221,563 total
    Exercise: $6.84Exp: 2034-05-06Common Stock (3,500 underlying)
  • Exercise/Conversion

    Employee Warrant (right to buy)

    [F5]
    2026-01-153,500192,992 total
    Exercise: $7.80Exp: 2034-07-14Common Stock (3,500 underlying)
Footnotes (5)
  • [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025.
  • [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.86 to $31.85, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4.
  • [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.86 to $32.71, inclusive.
  • [F4]The option vests as to 1/4 of the underlying shares on April 18, 2025 and as to 1/48 of the underlying shares monthly from April 18, 2025.
  • [F5]The warrant vests as to 1/4 of the underlying shares on April 18, 2025 and as to 1/48 of the underlying shares monthly from April 18, 2025.
Signature
/s/ Paul Quinlan, as attorney-in-fact for Joana Goncalves|2026-01-16

Issuer

Oruka Therapeutics, Inc.

CIK 0000907654

Entity typeother

Related Parties

1
  • filerCIK 0001756991

Filing Metadata

Form type
4
Filed
Jan 15, 7:00 PM ET
Accepted
Jan 16, 5:26 PM ET
Size
14.3 KB